OverviewAudentes Therapeutics is a biotechnology company committed to the development and commercialization of innovative new gene therapy treatments for people with serious rare diseases. We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
We currently have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT307 for the treatment of CASQ2-related Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and AT982 for the treatment of Pompe disease.
|Recent News||More >>|
|Upcoming Events||More >>|
|There are currently no events scheduled.|
|Primary IR Contact|
|Andrew H. Chang|
Director, Investor Relations
Audentes Therapeutics, Inc.
Data provided by Nasdaq. Minimum 15 minutes delayed.